Meeting
2018 ASCO Annual Meeting
A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies.
Authors
Neelima Vidula
UC San Francisco, San Francisco, CA
Neelima Vidula , Andrei Goga , Jimmy Hwang , Minetta C. Liu , Ben Ho Park , Rita Nanda , Paula Raffin Pohlmann , Anna Maria Storniolo , Adam Brufsky , Vandana Gupta Abramson , Hope S. Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT03095352
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS1113)
DOI
10.1200/JCO.2018.36.15_suppl.TPS1113
Abstract #
TPS1113
Poster Bd #
187b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.
First Author: Neelima Vidula
Poster
2020 ASCO Virtual Scientific Program
Immunotherapy and chemotherapy combination for chest wall disease: TBCRC 044 trial.
First Author: Neelima Vidula
Poster
2023 ASCO Annual Meeting
Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer.
First Author: Shipra Gandhi
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).
First Author: Matt D. Galsky